Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib + FOLFIRI in second-line metastatic colorectal cancer
NCT02605044Phase 3Terminated
- Sponsor
- AB Science
- Start
- Jan 2014
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in metastatic colorectal cancer (mCRC) comparing Masitinib + FOLFIRI with Placebo + FOLFIRI (2 arms). Primary endpoint: Overall Survival at 60 months. Started Jan 2014; status: terminated.
02
Drugs
masitinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02605044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02605044.